These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36355830)
1. Opportunities and challenges for the development of M Nguyen HTM; van der Westhuizen ET; Langmead CJ; Tobin AB; Sexton PM; Christopoulos A; Valant C Br J Pharmacol; 2024 Jul; 181(14):2114-2142. PubMed ID: 36355830 [TBL] [Abstract][Full Text] [Related]
2. Diverse Effects on M Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356 [TBL] [Abstract][Full Text] [Related]
3. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. Davie BJ; Christopoulos A; Scammells PJ ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787 [TBL] [Abstract][Full Text] [Related]
4. Probing the binding site of novel selective positive allosteric modulators at the M Khajehali E; Valant C; Jörg M; Tobin AB; Conn PJ; Lindsley CW; Sexton PM; Scammells PJ; Christopoulos A Biochem Pharmacol; 2018 Aug; 154():243-254. PubMed ID: 29777683 [TBL] [Abstract][Full Text] [Related]
5. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease? Scarpa M; Hesse S; Bradley SJ Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of TAK-071, a muscarinic M Kurimoto E; Yamada R; Hirakawa T; Kimura H Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders. Saito A; Alvi S; Valant C; Christopoulos A; Carbone SE; Poole DP Br J Pharmacol; 2024 Jul; 181(14):2232-2246. PubMed ID: 36565295 [TBL] [Abstract][Full Text] [Related]
10. Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia. Lu Y; Hatzipantelis CJ; Langmead CJ; Stewart GD Br J Pharmacol; 2024 Jul; 181(14):2095-2113. PubMed ID: 37605621 [TBL] [Abstract][Full Text] [Related]
11. Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease. Chintamaneni PK; Krishnamurthy PT; Rao PV; Pindiprolu SS Med Hypotheses; 2017 Apr; 101():17-22. PubMed ID: 28351483 [TBL] [Abstract][Full Text] [Related]
16. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397 [TBL] [Abstract][Full Text] [Related]
17. SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs). Kuduk SD; Beshore DC Curr Top Med Chem; 2014; 14(15):1738-54. PubMed ID: 25176125 [TBL] [Abstract][Full Text] [Related]
18. Highlights and hot topics in GPCR research from 'Down Under'. Smith NJ; May LT; Grimsey NL Br J Pharmacol; 2024 Jul; 181(14):2091-2094. PubMed ID: 38798136 [TBL] [Abstract][Full Text] [Related]
19. T-495, a novel low cooperative M Mandai T; Sako Y; Kurimoto E; Shimizu Y; Nakamura M; Fushimi M; Maeda R; Miyamoto M; Kimura H Pharmacol Res Perspect; 2020 Feb; 8(1):e00560. PubMed ID: 31990455 [TBL] [Abstract][Full Text] [Related]
20. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Teal LB; Gould RW; Felts AS; Jones CK Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]